Quick Answer
Eton Pharmaceuticals, Inc. reported Gross Profit of $42.74 million for fiscal year 2025.
Eton Pharmaceuticals, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $42.74M | +82.6% |
| 2024 | $23.41M | +11.2% |
| 2023 | $21.06M | +47.1% |
| 2022 | $14.32M | -24.7% |
| 2021 | $19.00M | +4887.2% |
| 2020 | -$397.0K | -178.5% |
| 2019 | $506.0K | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.86M | +24.6% | -34.1% |
| June 30, 2025 | $11.92M | +111.9% | +20.9% |
| March 31, 2025 | $9.86M | +96.9% | +56.5% |
| September 30, 2024 | $6.30M | +43.1% | +12.0% |
| June 30, 2024 | $5.63M | -41.9% | +12.4% |
| March 31, 2024 | $5.01M | +49.6% | +13.7% |
| September 30, 2023 | $4.40M | +118.2% | -54.5% |
| June 30, 2023 | $9.68M | +109.9% | +189.4% |
- Eton Pharmaceuticals, Inc. showed an increase of +82.6% in Gross Profit compared to the prior fiscal year.
- Over the 2019–2025 period, Eton Pharmaceuticals, Inc.’s gross profit has grown by 8346.6% (from $506.0 thousand to $42.74 million).
- The most recent figure is from Eton Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: